摘要
目的探讨解聚素-金属蛋白酶19水平与神经胶质瘤诊断、预后的相关性。方法收集初诊为原发神经胶质瘤的患者49例,回顾性分析胶质瘤ADAM-19的表达与临床因素的相关性,并结合远期随访结果对胶质瘤ADAM-19的表达水平与生存时间进行比较。结果 ADAM19的相对表达率在各组间的表达从小到大排列为对照组(0.57±0.13)<胶质瘤Ⅰ~Ⅱ级(1.24±0.46)<胶质瘤Ⅲ~Ⅳ级(3.78±0.85)。胶质瘤分型Ⅰ~Ⅱ组,ADAM-19低表达人数及所占比例明显高于高表达人数及比例(17/20 vs 3/20);相反的趋势可见于WHO分型Ⅲ~Ⅳ组(6/29 vs 23/29)。ADAM-19高表达组的平均生存时间为(28.44±2.41)个月,明显低于低表达组(43.58±4.27)个月,P<0.05。结论胶质瘤ADAM-19的表达与预后、WHO分级相关。
Objective To evaluate the association between ADAM 19 and the prognosis and diagnosis of glioma .Meth-ods 49 patients with glioma were collected .The association between the expression of ADAM 19 in glioma and clinical factors were retrospectively analyzed .The expression of ADAM19 and survival were compared during follow up .Results The expression of ADAM19 showed the highest level in WHO Ⅲ~Ⅳclass compared with those of the control group and WHOⅠ~Ⅱclass.In addition,patients with low expression of ADAM 19 showed more percentage in WHO Ⅰ~Ⅱ class than those of WHO Ⅲ~ⅣClass,a reverse trend could be observed in WHO Ⅲ~Ⅳclass.Mean survival time of patients with high ADAM 19 expression was (28.44 ±2.41)months,which was significantly less than that of low ADAM19 expression (43.58 ±4.27)months, P<0.05. Conclusion ADAM19 expression in glioma is correlated with prognosis and WHO class .
出处
《实用癌症杂志》
2014年第12期1529-1531,共3页
The Practical Journal of Cancer
